Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegadricase - 3SBio/Cartesian Therapeutics

Drug Profile

Pegadricase - 3SBio/Cartesian Therapeutics

Alternative Names: Pegsitacase; Pegsiticase; PEGylated recombinant candida urate oxidase; SEL 037; SSS11; Uricase-PEG 20

Latest Information Update: 05 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phoenix Pharmacologics
  • Developer 3SBio; Cartesian Therapeutics
  • Class Enzymes; Oxidoreductases; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Urate oxidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tumour lysis syndrome; Lesch-Nyhan syndrome; Gout
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout
  • Phase I/II Tumour lysis syndrome

Most Recent Events

  • 28 Nov 2022 No recent reports of development identified for phase-I development in Gout(In volunteers) in China (IV, Injection)
  • 28 Nov 2020 No recent reports of development identified for phase-I development in Gout(In volunteers) in China (IV, Infusion)
  • 09 Aug 2019 Shenyang Sunshine Pharmaceutical plans a phase I pharmacokinetic trial in Chinese healthy volunteers in China in August 2019 (NCT04047394)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top